Assembly Biosciences has evolved into a well-funded antiviral development platform, supported by a strategic partnership with Gilead and a strong balance sheet. Its pipeline targets diseases with high unmet needs such as recurrent genital herpes, HDV, and cholestatic liver diseases, showing promising early clinical data. With over $340 million in pro forma liquidity after a recent offering, the company can fund operations through 2028 without needing near-term capital. Despite these strengths and upcoming Phase 2/3 catalysts, Assembly Biosciences trades at a valuation discount compared to peers.
Bitget is implementing compliance measures in three phases against 16 crypto platforms, including HTX and EXMO, aligning with Binance and responding to US and EU sanctions related to Iran and Russia. HTX disputes the restrictions, claiming they only ...
Former Binance CEO Changpeng Zhao (CZ) highlighted that Bitcoin's circulating supply has reached over 20.07 million out of the 21 million maximum, leaving less than 5% available. He estimates that 10-20% of all mined Bitcoin are permanently lost due ...
Bitcoin has mined about 20.07 million BTC since 2009, leaving roughly 929,465 BTC yet to be mined under the 21 million cap. Due to programmed halving events every four years, mining rewards are cut in half, slowing new issuance significantly. The nex...
SpaceX shares have fallen 33% from their highest point, reflecting market volatility or investor concerns. Despite this, Elon Musk projects a massive revenue increase for the company, expecting it to grow 53-fold and reach $1 trillion by 2030. This a...
Harvard University's endowment paused its Bitcoin ETF selling in Q2 2026, maintaining 3,044,612 shares of BlackRock's iShares Bitcoin Trust (IBIT) valued at $101.4 million. This marks a break after two quarters of significant reductions. The endowmen...
